We are very excited to be partnering with Osteotech. As a leader in the osteobiologic market, Osteotech is the perfect partner for our BMAC product. Our two technologies have the potential to set a new standard for bone regeneration
PLYMOUTH, Mass. (PRWEB) March 13, 2008
The scientific literature establishes that successful bone regeneration is a combination of cells, signal proteins and a quality scaffold. The combination of Osteotech's biologic bone regeneration products with Harvest's BMAC will provide orthopedic surgeons a new powerful tool.
"We are very excited to be partnering with Osteotech. As a leader in the osteobiologic market, Osteotech is the perfect partner for our BMAC product. Our two technologies have the potential to set a new standard for bone regeneration," said Gary Tureski, President of Harvest Technologies.
Harvest Technologies has a rich tradition of innovative technologies that are designed to process and concentrate autologous cells and proteins. The BMAC system incorporates a proprietary floating-shelf technology that provides the highest total nuclear cell yield with established viability and osteogenicity. (1,2)
Until the introduction of Harvest's BMAC(TM) System, it was difficult to process and concentrate a clinically significant dose of adult stem cells from a patient's bone marrow at the point of patient care within 15 minutes.
Harvest Technologies is a privately held company based in Plymouth, Mass.
1 Osteogenic differentiation model, performed at the CBR Institute of Biomedical Research, Boston, 2006. 2 Heeschen, Christopher M.D, et al. Concentration of Bone Marrow Total Nucleated Cells by a Point of Care Device Provides a High Yield and Preserves Their Functional Activity. Cell Transplantation, Vol 16. pp-159-1069, 2008.